Sequana Medical announces Annual and Extraordinary General Meetings of Shareholders on 27 May 2022
April 27, 2022 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION27 April 2022, 07:00 am CEST Publication of Annual Report 2021 Ghent, Belgium – 27 April 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or...
Sequana Medical announces 2021 Full Year Results and 2022 Outlook
April 12, 2022 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION12 April 2022, 07:00 CET alfapump® in liver disease Positive results from second interim analysis of POSEIDON pivotal study; encouraging survival data at 12 months...
Sequana Medical to present at Needham’s Healthcare Conference and attend Kempen’s Life Sciences Conference in April 2022
April 08, 2022 01:00 ET
|
Sequana Medical NV
Ghent, Belgium – 8 April 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid overload in liver disease,...
Sequana Medical announces the completion of alfapump implantations in POSEIDON, the North American pivotal alfapump study
April 05, 2022 01:00 ET
|
Sequana Medical NV
Reporting of primary endpoint on track for Q4 2022FDA regulatory submission on track for mid-202370% survival of POSEIDON Roll-In patients at one year post-implantation1 compares favourably to...
Sequana Medical Notice of 2021 Full Year Results and Business Update
March 31, 2022 01:00 ET
|
Sequana Medical NV
Ghent, Belgium – 31 March 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid overload in liver...
Transparency Notifications from Shareholders
March 28, 2022 12:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION 28 March 2022, 6 p.m. CET Ghent, Belgium – 28 March 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in...
Transparency Notifications from Shareholders
March 18, 2022 13:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION 18 March 2022, 6 p.m. CET Ghent, Belgium – 18 March 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in...
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
March 10, 2022 12:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION10 March 2022, 18:00 CET Ghent, Belgium, 10 March 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in the...
Sequana Medical to present at BioCapital Europe and Oppenheimer’s Annual Healthcare Conference
March 09, 2022 01:00 ET
|
Sequana Medical NV
Ghent, Belgium – 09 March 2022 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver...
SEQUANA MEDICAL SUCCESSFULLY RAISES EUR 28.4 MILLION IN AN EQUITY PLACEMENT
March 08, 2022 01:00 ET
|
Sequana Medical NV
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED...